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Clinical immunology has developed very significantly 
as a speciality over the last twenty years, as has the 
understanding of the immunological basis of many diseases 
and the development of immunological therapies. Indeed it 
is difficult to think of a speciality that has not developed an 
“immunological dimension” in this time.
The purpose of this mini-review is to update the non-
specialist reader on the basic immunological mechanisms 
which underlie an effective immune response and the clinical 
disorders which results when the processes are deficient or 
disordered. The basic science description is, of necessity 
limited in scope and detail.  Further explanation of the basic 
cellular and molecular mechanisms involved in immune 
defence can be found in recent textbooks1,2.
Innate and adaptive immunity
Innate immune defences are the body’s constant, unchanging 
defence against infection. These are non-specific and include 
physical components such as skin, mucous membranes, gastric 
acid, nasal cilia etc as well as phagocytic cells and proteins 
of the complement system. In contrast, the adaptive immune 
system includes lymphocytes and immunoglobulin (antibody) 
molecules which share characteristics of specificity and 
memory. The components of the adaptive system recognise 
and are stimulated by specific fragments of microorganisms 
termed antigens (from Antibody Generating). When antigens 
are appropriately presented to lymphocytes  by specialist 
antigen presenting cells (APC: see below), they generate 
antigen specific T cells and B cells that develop to produce 
antibody molecules. 
There are five isotypes of immunoglobulin, or antibody, 
molecules: IgG, IgM, IgA, IgD and IgE. All five share a basic 
“Y- shaped” structure (Figure 1) although IgM and IgA tend 
to exist in pentameric or dimeric forms. IgG is the major 
isotype present in serum, IgA has a crucial role at mucous 
membranes and IgM is the isotype that dominates the primary 
antibody response to first encountering a foreign antigen. 
IgD molecules function as cell surface receptors and IgE, 
whilst important in protection from parasitic infection is most 
notable in western societies for its role in allergic or type 1 
hypersensitivity disease. 
The normal peripheral blood lymphocyte population 
comprises 70-90% T cells; 5-10% B cells and 1-10% natural 
killer (NK) cells. These are all derived from lymphoid stem 
cells in the bone marrow. Lymphocyte subsets are defined 
by their expression of surface markers termed CD antigens 
(CD: cluster of differentiation). T cells are classified by their 
cell surface markers as CD3+, with the helper subset (Th) 
defined as CD3+CD4+ and the cytotoxic subset (Tctx) as 
CD3+CD8+. There are also a number of regulatory T cell 
subsets which are described below. B cells are CD19+ and 
Fig 1. The basic structure of IgG1. The n terminal end of the heavy 
and light chains is the variable region responsible for antigen 
binding (Fab). The Fc region is responsible for complement (C1q) 
activation and binding to cell surfaces via Fc receptors.
Fig 2. Activation of CD4+ T cells. In addition to antigen 
recognition via the T cell receptor(TCR), a range of cell surface 
molecules and soluble cytokines deliver additional positive (+) or 
negative (-) signals. Interleukin 2 (IL-2) secretion activates both 
the secreting T cell (autocrine) and it’s near neighbours (paracrine)© The Ulster Medical Society, 2011.
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NK cells CD16+CD56+. 
Immature T cells emerge from the bone marrow and undergo 
maturation during their passage through the infant’s thymus 
gland. During that maturation, T cells with specificity for 
“self antigens” are deleted and only those with appropriate 
reactivity to foreign antigens complete their passage to 
the peripheral circulation. This is one of the “central” 
mechanisms of inducing “self-tolerance” and preventing 
autoreactivity against self antigens. 
The process of developing specific immunological responses 
to microorganisms involves elements of both the innate 
and adaptive immune systems. Innate cells with phagocytic 
function recognise and engulf (phagocytose) invading 
microorganisms. Once phagocytosed, the microorganisms 
are broken down into short amino acid sequences which 
ultimately stimulate an immune response through a process 
of antigen presentation to lymphocytes (Figure 2). 
Mature T cells recognise antigenic fragments/ peptides, only 
when they are presented to them bound to one of the major 
histocompatibility complex (MHC) molecules (MHC Class 
1 or 2). MHC molecules are coded for by a discrete area on 
the short arm of chromosome 6 and have central roles in 
enabling the body to distinguish the recognition of self from 
non-self molecules. MHC Class 1 molecules are expressed on 
all nucleated cells, whereas MHC Class 2 are only expressed 
on specialist antigen presenting cells (APC). Each type 
of MHC molecule binds antigen fragments and presents 
these to their respective T cell subset. CD4+ Th cells only 
recognise antigen presented in the context of MHC Class 
2 molecules whilst CD8+ Tctx cells only recognise antigen 
fragments in the context of MHC Class 1 molecules. The 
specific binding of the T cell receptor to antigen presented in 
the peptide binding groove of the MHC molecules leads to 
cellular activation. There are a also a number of non-specific 
co-stimulatory cell surface molecules that serve to enhance 
the binding and influence the nature of the cellular activation 
(Figure 2). The fact that T cells only respond effectively 
when antigen is appropriately presented is termed MHC 
restriction, and it is important to understand as it relates to 
the major functions of the two main cellular subpopulations. 
CD4+Th cells are central co-ordinators of the immune 
response, only being activated by specialist APC cells. 
CD8+Tctx cells are effectors, and therefore must be capable 
of recognising infection or malignant transformation of any 
nucleated cell in the body.  
CD4+ Th cells stimulate B cells both by direct cell surface 
interaction but also by the secretion of cytokines. Cytokines 
are low molecular weight polypeptides that act to provide inter 
cellular signals. Most are known as interleukins (meaning 
that they effect communication between white blood cells) 
and are numbered in the order in which they were discovered. 
So, interleukin 2 (IL-2) is an important activator of T cells 
and was discovered before interleukin 8 (IL-8) which has an 
important role in recruiting neutrophils.  Cytokines may affect 
the cell that produced them (autocrine effect) or other cells in 
their immediate vicinity (paracrine effect) but generally have 
little influence on cells at distant locations (endocrine effect).
The interaction of APC, CD4+ T cells and B cells is central 
to the adaptive response to pathogens resulting in primary 
and secondary antibody responses (Figure 3). The first or 
primary exposure to a microorganism is characterised chiefly 
by production of antigen specific IgM , however on secondary 
exposure, memory B cells are stimulated and high levels of 
protective IgG are produced. It is that highly specific, high 
titre IgG that provides long term protection. 
T cell regulation
It is important that once an immune response is initiated, there 
are mechanisms to control and/or limit reactivity to prevent 
Table 1: 
UK Immunisation Schedule (www.immunisation.co.uk)
2 months:
•	 Diphtheria, tetanus, pertussis (whooping cough), 
polio and Haemophilus influenzae type b given as 
a 5-in-1 single jab known as DTaP/IPV/Hib 
•	 Pneumococcal infection  
3 months:                     
•	 5-in-1, second dose (DTaP/IPV/Hib) 
•	 Meningitis C 
4 months:
•	 5-in-1, third dose (DTaP/IPV/Hib) 
•	 Pneumococcal infection, second dose 
•	 Meningitis C, second dose 
Around 12 months:
•	 Meningitis C, third dose 
•	 Hib, fourth dose (Hib/MenC given as a single jab) 
Around 13 months:
•	 MMR (measles, mumps and rubella), given as a 
single jab 
•	 Pneumococcal infection, third dose 
3 years and 4 months, or soon after:
•	 MMR second jab 
•	 Diphtheria, tetanus, pertussis and polio (DtaP/
IPV), given as a 4-in-1 pre-school booster 
Around 12-13 years:
•	 Cervical cancer (HPV) vaccine (girls only): three 
jabs given within six months 
Around 13-18 years:
•	 Diphtheria, tetanus and polio booster (Td/IPV), 
given as a single jab 
65 and over:
•	 Flu (every year) 
•	 Pneumococcal© The Ulster Medical Society, 2011.
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uncontrolled or inappropriate immunological activation and 
potentially harmful inflammatory reactions. In terms of 
responses to microorganisms, the destruction and eradication 
of the microorganism itself is an important mechanism for 
“switching off” an immune response. 
Within the population of CD4+ Th cells there is further 
differentiation into different functional subpopulations which 
have various regulatory functions. T helper 0, 1 and 2 (Th0, 
Th1 and Th2) subdivisions are defined by their preferential 
patterns of cytokine secretion and their differing influences on 
ultimate nature of the immune response to a pathogen. Th0 
differentiate into either Th1 or Th2. The Th1 cytokines are 
IL-2, IL-12 and IFN-γ favouring a cellular immune response 
whilst the Th2 cytokines, favouring an antibody response, 
are IL-4, IL-5, IL-6 and IL-10. There is mutual suppression 
between these two dominant patterns of cytokine secretion 
such that, once a response has become committed in either 
direction, this pattern will tend to be maintained (Fig 4). The 
secretion of IL-4 and IL-5 tends to promote eosinophilia and 
IgE production and therefore Th2 responses are associated 
with type 1 hypersensitivity reactions and allergy. Other 
clinical examples of the consequences of  Th1/Th2 response 
include the response to protozoal and mycobacterial infection. 
In lepromatous leprosy, there is a dominant Th2 response to 
the mycobacterium, which results in poor cytotoxic killing, 
high microbiological load and poor granuloma formation. 
In contrast, in granulomatous disease, there is a dominant 
Th1 response, potent cytotoxic response with localisation 
of microorganisms within an inflammatory granuloma and 
a consequently low mycobacterial count. There are other 
direct clinical consequences of this understanding of T cell 
functions. In some specific primary immunodeficiency states, 
there is an inability to mount effective Th1 type responses 
because of deficiency in either interferon γ or IL-12 secretion 
or responses. In such patients, replacement or supplementary 
treatment with interferon can be life saving. In other clinical 
situations e.g. multidrug resistant tuberculosis or eradication 
of non-tuberculous mycobacteria from the bronchiectatic 
lung, adjunctive interferon γ therapy can be similarly effective 
through boosting of the Th1 response. 
The concept of “central tolerance” has already been 
mentioned, however “peripheral tolerance” also occurs as 
a means of maintaining control of potentially autoreactive 
lymphocytes3. The population of CD4+CD25+ (CD25 is the 
IL-2 receptor and is a marker of “activated” T cells) regulatory 
cells are also important in controlling self reactive responses 
and abnormalities in this population may predispose to 
autoreactivity and autoimmunity4,5. 
The  Th17 population is relatively recently described cell 
subset also thought to be involved in development of 
autoimmunity, particularly multiple sclerosis, diabetes, 
psoriasis and Rheumatoid arthritis6.  Th17 are probably 
developmentally distinct from Th1 and Th2 cells and they 
preferentially produce cytokines IL-17, IL-21 and IL-22. 
Their pro-inflammatory functions may indicate an important 
role in protective immunity at mucosal sites and they are 
thought to be down regulated by both Th1 and Th2 subsets7,8. 
Immunology of the newborn 
The newborn infant is immunologically immature and 
depends on its innate immune defences and passively 
acquired maternal immunoglobulin G (IgG).  Newborn 
infants, particularly those born prematurely, who have not 
had adequate transfer of maternal immunoglobulin in the last 
trimester of pregnancy, are therefore vulnerable to developing 
infection. 
Maternally acquired IgG binds specifically to the wide 
range of microorganisms already encountered by the mother 
and is a form of passive immunity. It provides immediate 
wide-ranging protection until the natural process of antigen 
exposure has stimulated the production of endogenous 
antibody by primary and secondary responses. The half 
life of IgG is approximately 3 weeks in vivo and typically, 
maternally derived immunoglobulin levels will wane and 
fall so that the newborn reaches an immunological nadir 
of serum immunoglobulin levels between 3 to 6 months of 
age. At this stage the infant is most vulnerable to infection. 
If the production of immunoglobulin is abnormally delayed, 
the infant can develop transient hypogammaglobulinaemia 
of infancy (THI), which may require treatment with 
immunoglobulin replacement therapy should significant 
infection occur. It is crucial that THI is differentiated 
from one of the potentially life threatening Primary 
Immunodeficiency Disorders (PID: see below) that typically 
present in the first year of life. THI is therefore a diagnosis 
of exclusion.
Infant Immunisation
The UK immunisation schedule (Table 1) has been developed 
to protect the population from common infectious disease 
with potential for significant morbidity and mortality. The 
schedule is under regular review and is updated as new 
vaccines are developed. For most infectious agents, a series 
of vaccine doses is required, given at intervals, to generate 
a high level of protective antibodies. Underlying this is the 
concept of the primary and secondary antibody response of 
the adaptive immune system (Figure 3). Individual vaccines 
vary in their immunogenicity and the dosing and booster 
schedules are therefore individually determined to maintain 
appropriately high protective antibody levels.
Immune deficiency
Development failure of immune system components, or 
breakdown in its control can lead to the development of a 
wide range of primary immune deficiencies (PID). Figure 
5 indicates how immune deficiencies arise as a result of 
failure of development or depletion of T cells at different 
stages of development (ontogeny). Whilst many PID present 
in childhood, they can present at any age in life and can 
affect individual components of the immune system e.g. 
immunoglobulin molecules9, complement components10, 
neutrophils11 or lymphocytes or they can be combined 
deficiencies affecting both lymphocyte and immunoglobulin 
numbers and levels12. 
The most common PID are those characterised by deficiency 
of immunoglobulins (IgG, IgA or IgM). The most common 
type of antibody deficiency is common variable immune 
deficiency (CVID). CVID usually presents in children or 
young adults with a prolonged history of recurrent upper 
and lower respiratory tract infections, although it may also © The Ulster Medical Society, 2011.
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present with autoimmune disorders affecting the GI tract, 
haematological or endocrine systems. An important aim for 
CVID patients is to establish the diagnosis and commence 
treatment before recognised complications of the disorder 
e.g. bronchiectasis have developed. A UK wide audit in 1996 
suggested that the average diagnostic delay for such patients 
was of the order of 7 years, however anecdotally we know 
the delay can be much longer for individual patients13,14. 
Commencement of immunoglobulin replacement therapy by 
either the intravenous (IvIg) or subcutaneous (ScIg) routes is 
highly efficacious in reducing the number of infections and 
therefore preventing the development of complications15. IvIg 
and ScIg are usually lifelong treatments and may both be 
self administered at home after appropriate patient training. 
In Northern Ireland we currently have data on 218 patients 
with PID.  151 of these receive immunoglobulin replacement, 
around 80 of whom are treated at home (Table 2).
One of the few “immunological emergencies” and the 
most serious PID is severe combined immune deficiency 
(SCID). SCID usually presents during the first months of 
life. Affected infants are characterised by failure to thrive, 
recurrent bacterial, viral and/or fungal infections and there 
may be additional features including diarrhoea, rashes and 
liver dysfunction caused by graft versus host disease as 
well as morphological abnormalities. Graft versus host 
disease occurs in this context when functioning maternal 
lymphocytes transfer to the newborn at birth. The infant’s 
immune system is unable to eradicate these and instead these 
maternal lymphocytes go on to proliferate and attack skin, 
liver and gut, resulting in a syndrome very similar to that 
seen after bone marrow transplantation. The acronym SCID 
can erroneously suggest a clinical presentation so severe and 
so rare, that an average paediatrician is unlikely to encounter 
the condition. This is however not the case and whilst SCID 
is rare, as is the case for other PID, it is almost certainly 
under diagnosed. There may be several factors contributing 
to the under diagnosis of SCID. Affected infants may initially 
appear relatively well, with perhaps frequent attendances 
related only to symptoms of relatively mild viral infection, 
diarrhoea or oral/perineal thrush. Identification of infants at 
high risk of SCID is therefore difficult, but one should have 
a higher index of suspicion if the parents are from a cultural 
background in which first cousin marriage is common (e.g. 
the Indian subcontinent). It should be emphasised that 
children with SCID do not typically have absent lymphocytes 
and/or immunoglobulins. Rather, their lymphocyte and 
Fig 3. Primary and secondary antibody responses typify the 
adaptive immune response to antigen. Memory cells generated 
from the primary response become rapidly activated upon re-
exposure to the same antigen.
Fig 4. T cells differentiate along two major axes depending on their 
pattern of cytokine secretion. To give T helper 1(Th1) cells, which 
tend to promote cellular responses, and T helper 2 (Th2) cells whch 
tend to promote antibody production and IgE mediated responses. 
Th1 and Th2 cells are mutually suppressive. The distinction 
between these two subpopulations is not absolute in humans.
Table 2 
Patients on treatment for Primary immunodeficiency & auto 
inflammatory syndromes in Northern Ireland, 2010
Common variable Immune deficiency (CVID)  93
C1-inhibitor deficiency  27
X-linked agammaglobulinaemia (XLA)        22
Other hypogammaglobulinaemia  14
Specific antibody deficiency  11
IgG subclass deficiency/IgA deficiency  9
Wiskott-Aldrich syndrome  4
Autoimmune polyendocrinopathy and 
chronic ectodermal dysplasia (APECED)  4
Severe combined immune deficiency (SCID)  4
Ataxia Telangectasia  4
Good’s syndrome  3
Interferon gamma receptor deficiencies (IFNgR1 def)  3
X-linked Hyper IgM (XHIGM)  3
Hyper IgD syndrome  3
Autoimmune lymphoproliferative syndrome (ALPS)  3
Chronic mucocutaneous candidiasis (CMC)   2 
Chronic granulomatous disease  2
Complement deficiencies  2
Idiopathic CD4 cytopaenia  2
Schnitzler syndrome  1
Immune dysfunction, Polyendocrinopathy,  
Enteropathy, X-linked (IPEX)  1
X-linked lymphoproliferative disease (XLP)  1© The Ulster Medical Society, 2011.
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immunoglobulin levels are well below normal age-related 
reference ranges. A useful guide is that any child with a total 
lymphocyte count of <2.8 x109/L should be investigated for 
SCID, although a normal lymphocyte count does not exclude 
the diagnosis.  We assess children for SCID on a regular basis 
and probably make the diagnosis at least once every year. If 
diagnosed early and managed appropriately, including early 
bone marrow transplant, long term survival from the disorder 
is currently of the order of > 85%. 
Under diagnosis is a major problem for patients with PID. 
There is also significant geographical variation in perceived 
prevalence across the UK which is probably at least partly 
explained by the patchy provision of immunology services. 
In Northern Ireland there were approx 25 patients diagnosed 
with PID in 1996, and this has risen to over 200 patients in 
2010. This relentless annual rise in the number of diagnosed 
cases shows no signs of abating. 
Whilst the most severe conditions require bone marrow 
transplantation16, others are managed with regular 
immunoglobulin replacement therapy, enzyme replacement   
therapy, cytokine treatments or prophylactic antibiotics. Many 
of these disorders are on the basis of single gene defects and 
PID  have been the candidate conditions in which much of 
the success in clinical trials of somatic gene therapy has been 
achieved.
Understanding of the prevalence of PID across the UK is 
limited and this is currently being addressed through the 
establishment of a UK-PID registry under the auspices of the 
UK primary immunodeficiency network (www.ukpin.org.uk). 
Servers for this project went live in 2009 and already approx 
1300 out of an estimated 5000 patients have been registered. 
Across Europe, the linked database of the European Society 
for Immune Deficiency (http://www.esid.org/statistics.php) 
established in 2004 has details of over 12,000 PID patients.
Allergy
Allergic disease is a much more common clinical problem 
than PID and a source of considerable workload in primary 
care, organ based specialities (eg ENT, dermatology & 
respiratory medicine) as well as clinical immunology services. 
The spectrum of allergic disease seen in specialist allergy 
clinics includes potentially life threatening anaphylaxis, drug 
and venom allergy and complex multisystem allergic disease. 
A particular problem is the patient with chronic urticaria 
and /or angioedema of uncertain aetiology and that will be 
specifically addressed below.
Is the rise in allergic disease real?
It is sometimes suggested that the apparent rise in allergic 
disease is due to greater awareness and hence increased rates 
of diagnosis. However there is a well documented rise in the 
prevalence of allergic disease in “westernised” societies, but 
not in most of the less industrialised regions including Africa, 
India and South East Asia. Why should this be the case? It 
is recognised that societies with a high prevalence of allergy 
tend to have smaller family sizes, lower rates of infectious 
disease in infancy, higher rates of immunisation and greater 
degrees of domestic cleanliness. The Hygiene Hypothesis 
suggests that all of these factors lead to a decreased rate 
of microbial turnover at the infant’s mucosal sites and that 
this in turn promotes abnormal immunological responses to 
antigens encountered, be they inhaled (pollens, animal dander, 
house dust mite) or ingested (foods)17,18. Allergic disease is 
Table 3: 
Gell & Coombs classification of hypersensitivity
Type of 
Reaction
Effector 
Mechanism
Clinical Disorder
I IgE, Mast cells Allergic rhinitis, urticaria, 
angioedema, anaphylaxis
II IgG directed 
at cell surface 
bound antigen
Transfusion reactions, 
acute graft rejection, 
Graves disease, 
Myasthenia Gravis, 
goodpasture’s syndrome
III Immune 
complexes
Cryoglobulinaemia, 
post-streptococcal 
glomerulonephritis, 
systemic lupus 
erythematosus
IV CD4+ 
lymphocytes
Delayed type 
hypersensitivity, contact 
eczema, granulomatous 
reactions
CD8
CD4
Thymus
Reticular 
Dysgenesis X-SCID
MHC Class II 
deficiency
Lymphocyte 
stem cell
Pre T
cell
Di George 
Syndrome
ADA & PNP 
Deficiency
Ataxia-telangectasia
HIV
Hyper IgM
BM 
Stem cell
Fig 5. T cell development and Immunodeficiency
Fig 6. Antigen cross links specific IgE molecules on the surface 
of Mast cells causing degranulation and release of multiple 
mediators including histamine, heparin, platelet activating factor 
and leukotrienes. These mediators cause different symptoms 
depending on the anatomical site of release.© The Ulster Medical Society, 2011.
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therefore characterised by the presence of antigen specific 
IgE to (usually) innocuous antigen and is the end result of a 
disordered immune response. 
What is the cellular basis for allergy?
As already stated, Th2 cytokines, in particular IL-4 & 5 
tend to promote IgE mediated responses to antigens. Once 
produced, antigen (or allergen) specific IgE binds via 
specialised receptors to the surface of mast cells. When 
later exposure to the allergen occurs, the IgE molecules are 
cross linked causing mast cell degranulation and the release 
of histamine and other mediators (leukotrienes, heparin, 
platelet activating factor etc) into the local tissue (Figure 6). 
These mediators have a wide range of effects and depending 
on the site of allergen exposure and location of mast cells 
activated, the resulting symptoms may include eg: rhinitis, 
conjunctivitis, urticaria, angioedema, vomiting, diarrhoea or 
anaphylactic shock.
Clinical Allergy
The increasing prevalence of allergic disorders represents 
a great challenge to the health service. Most medical 
practitioners have little or no formal training in allergic 
disease, however they are aware of the potentially severe 
nature of some allergic reactions. Paediatricians have 
historically taken an interest in food allergy and in Northern 
Ireland there is now a network of paediatricians with an 
interest in allergy, with at least one consultant in most of our 
hospitals.
The spectrum of allergic disease is wide; however the 
underlying mechanisms are common to most. The term 
allergy is widely misused in the popular press to refer to any 
adverse reaction. However in this context, allergy means Type 
1 hypersensitivity (from the Gell & Coombs classification: 
Table 3)
Urticaria
Urticaria is caused when mast cells are activated in the 
epidermis. It is commonly described as resembling “nettle 
stings” and is typically raised and intensely itchy (Figure 
7). It may occur as part of an acute allergic reaction or be 
a chronic problem, occurring on an almost daily basis for 
at least 6 weeks (chronic idiopathic urticaria / CIU ). In 
patients with CIU it is very rare to identify an allergen and 
extensive laboratory investigation of such patients is not 
usually recommended. Management is usually with prolonged 
courses of non-sedating oral antihistamines, often at 3-4 times 
the recommended dose, to obtain complete suppression of the 
rash. Several variants of CIU occur, including autoimmune 
urticaria, urticarial vasculitis and physical urticarias. Good 
guidance is available on their diagnosis and management19. 
Angioedema
Angioedema is a non-dependent, non-pitting swelling that can 
affect any part of the body but frequently affects the perioral 
and periorbital regions, tongue, genitalia and peripheries such 
as the hands and feet. It can also occur internally causing 
laryngeal oedema or acute intestinal obstruction. Mast cell 
activation in the deep dermis is the usual cause; however 
in addition to histamine release, increased generation or 
reduced degradation of bradykinin is thought to be a key 
causative factor. Angioedema and urticaria commonly occur 
in the same person either as part of an acute allergic reaction 
or in approximately 40% of people with CIU. Management 
of the latter group is the same as for CIU. Approx 10% of 
“CIU patients” have chronic angioedema but no urticaria. 
Two important variants exist which are distinct in terms of 
both aetiology and treatment. Angiotensin converting enzyme 
inhibitors (ACEi) can cause potentially life threatening 
angioedema and the history is not typical of an allergic 
mechanism. In such patients, angioedema usually occurs after 
prolonged ACEi treatment, the swelling is not related in time 
to taking the medication and in some people, swelling may 
persist for some time after withdrawal of the drug. Anyone 
presenting with angioedema whilst taking an ACEi, must 
have alternative anti hypertensive drugs prescribed. There 
is a smaller but well described risk of angioedema with 
the Angiotensin II receptor blocking drugs and therefore 
alternatives such as calcium channel blockers and Beta 
blockers are preferred if possible. 
Partial deficiency of the complement control protein C1 
esterase inhibitor (C1-inh) also leads to recurrent angioedema 
in genetically affected individuals. Although C1-inh 
deficiency causes a loss of control of the activation of the 
classical complement pathway, it is via its indirect effect on 
bradykinin metabolism that angioedema occurs. 
These patients are at risk of sudden death due to laryngeal 
oedema after intubation or dental treatment. They also suffer 
regular peripheral swellings and are frequently treated with 
either the prophylactic androgens danazol or stanozolol or 
the antifibrinolytic tranexamic acid. Acute laryngeal oedema 
requires administration of intravenous C1-inh concentrate. 
The angioedema of C1-inh deficiency does not respond to 
anti-histamines, corticosteroids or epinephrine. 
There are approx 27 patients with C1-inh deficiency in 
Northern Ireland and these families are well defined and 
have management plans that include the possession of C1-
inhibitor concentrate at home for emergency use. However it 
Table 4
Factors associated with fatal nut reactions
•	 Being away from home
•	 Eating food from commercial sources
•	 Not carrying rescue medication
•	 Alcohol
•	 Age: Between 15-25
•	 No deaths < 13 years (one series)
•	 Asthma 
	Excessive reliance on β2 agonists for 
asthma control 
	12 of 13 cases of fatal and near fatal 
reactions
	24 of 25 fatalities had asthma© The Ulster Medical Society, 2011.
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is important to note that in approx 33 % of new cases, there 
is no suggestive family history and the diagnosis rests on 
identifying typical angioedema, usually without urticaria and 
on testing, serum complement C4 levels are usually low as 
are levels of C1-inh enzyme. The diagnosis of C1-inhibitor 
deficiency is not uncommonly made late, in adulthood and 
therefore should be considered in any patient presenting with 
otherwise unexplained angioedema usually without urticaria.
Anaphylaxis
The term anaphylaxis originally indicated a state of 
susceptibility to severe allergic reactions and it was derived 
from  ana (against) and φ´ υλαξις  phylaxis (protection). 
Anaphylactic reactions are now defined as “severe, life-
threatening, generalised or systemic hypersensitivity 
reaction”. The usual defining clinical characteristics are 
significant airway obstruction or hypotension, but clinical 
features may include a sense of impending doom, urticaria, 
angioedema, abdominal pain, vomiting or diarrhoea. The 
route of exposure, dose and nature of the allergen as well 
as coexisting conditions such as asthma or infection and 
concomitant medications e.g. Beta blockers may all affect 
the dominant clinical features.  It is crucial that medical 
practitioners recognise anaphylactic reactions and treat them 
promptly to ensure the best chance of survival20
The underlying pathophysiology is the systemic activation of 
mast cells throughout the body. In the clinical diagnosis of 
allergic reactions this may be confirmed by the measurement 
of serum mast cell tryptase levels at the time of reaction (and 
2 and 24 hours later). Formal protocols exist both locally and 
nationally for the structured investigation of anaphylactic 
reactions e.g. during anaesthesia21 
Food allergy
Food allergy is often misunderstood and its prevalence 
overestimated. There is often confusion between food allergy 
and intolerance. True food allergy is common in early 
infancy with cow’s milk protein, egg white, wheat, shellfish, 
peanuts and tree nuts being common allergens. Diagnosis of 
food allergy in infancy rests on the typical clinical features, 
supported by specific IgE skin or blood testing. Most infants 
eventually outgrow their food allergies with the notable 
exception of peanut and tree nut allergy.
Peanut & tree nut allergy
Peanut and tree nut ( e.g. brazil, cashew  & hazel nuts, 
walnuts, almonds, pistachio etc) allergy came to the attention 
of the medical community in the UK in the late 1980’s and 
early 1990s. Initially, it was thought to be a rare condition, 
but the prevalence of peanut allergy rose significantly in the 
1990s such that now approx 1:75 pre-school children is said 
to be affected in the UK. There is great public awareness of 
the issue of peanut allergy both because of the precautions 
now taken e.g. in schools and commercial food suppliers and 
the small number of deaths that have occurred and received 
much media attention. Approximately 50% of peanut allergy 
sufferers will also report reactions to tree nuts. Some people 
are allergic to tree nuts but not peanuts, but the prevalence is 
not well defined and almost certainly varies between different 
tree nuts. Peanuts are in fact legumes and some peanut allergy 
sufferers will also react to cross reacting legumes including 
beans and peas.
What are the defining characteristics of peanut allergy?
Peanut allergy is often first noticed in infancy or early 
childhood, although onset can be at any age. It is usually a 
prolonged allergy, with sensitivity lasting into adulthood. 
Although there are published reports that up to 20% of 
affected children may outgrow this allergy this is not generally 
reflected in current clinical practice in the UK. For the most 
part we advise that one should assume peanut allergy is 
effectively a lifelong condition. It is recognised that there 
is a spectrum of severity of reactions with some individuals 
being exquisitely sensitive, reacting even to the smell of 
peanuts whilst others may be able to consume a small amount 
of peanut before reacting. The fact that severe reactions can 
be triggered by small amounts of nut antigen in some people 
causes great anxiety for patients and their families. 
Allergic reactions to nuts are almost universally of very rapid 
onset. Typically the individual will spit out the offending 
food or vomit. Reactions often involve angioedema of the 
perioral region, tongue or larynx with resultant respiratory 
difficulty. People with asthma will often experience wheeze. 
Hypotension can be profound. 
A popular misconception is that allergic reactions typically 
increase in severity over time and e.g. with peanut allergy 
that there is an inexorable increase in severity and that 
severe anaphylaxis will ultimately be unavoidable. This 
is not the case. In most people, if the circumstances and 
degree of exposure to allergen are similar, the reaction tends 
to be stereotypical. However there are a number of factors 
associated with increased risk of severe reactions and these 
are listed (Table 4). It is however important to emphasise that 
Table 5
Management advice for nut allergy 
(i)   A nut free environment at home 
(ii) Oral antihistamine for: 
a.  Inadvertent / presumed nut exposure
b.  Minor reactions: skin rash, non-life 
threatening angiodema 
c.  pre-medication
(iii)  Injectable adrenaline for   
a.  life threatening airway obstruction 
(includes severe asthmatic symptoms)
b.  anaphylactic collapse
(iv)  Warning device/card
(v) Emergency contacts in mobile phone: ICE (In case 
of emergency) / SOS
(vi)  Support information 
a.  www.anaphylaxis.org.uk 
b.  www.allergyni.co.uk 
c.  www.epipen.co.uk© The Ulster Medical Society, 2011.
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the vast majority of patients with peanut and nut allergy, who 
have been properly assessed at a specialist clinic, practice 
careful nut avoidance and have an effective management 
plan in place which includes rescue medication, manage their 
condition very effectively22. A summary of our management 
advice for patients with peanut allergy is also provided (Table 
5).
Although the potential severity of peanut allergy is widely 
recognised, deaths are fortunately rare. National audit data 
for the UK indicates that there are on average 2.6 deaths per 
year caused by peanut or tree nut allergy.23,24 
Desensitisation
Desensitisation (or allergen immunotherapy) is a therapeutic 
strategy which is aimed at reducing the degree of allergic 
sensitisation of an individual patient.  The basic approach 
is that the patient is exposed to minute amounts of the 
substance to which they are allergic on a regular basis, often 
over a prolonged period, typically three years. The result is 
that by regular, low dose exposure to allergen, the harmful 
IgE mediated allergic response is largely “switched” to an 
IgG (usually IgG4) protective response25. Allergen may 
be administered subcutaneously (SCIT), orally (OIT) or 
sublingually (SLIT). Pollen SCIT was widely practised in 
general practice the UK in the 1970s and 1980s however 
there were 17 deaths reported to the regulatory authorities 
and as a result, desensitisation is now highly regulated and 
restricted to specialist centres. In retrospect, it is felt that the 
deaths were at least in part due to inappropriate selection and 
monitoring of patients. It is worth noting that desensitisation 
has remained widely practiced in Europe and North America 
and is an effective therapeutic strategy26,27. Delivery of SCIT 
is however burdensome for both patients and doctors in terms 
of time commitment and precautions required. This is a major 
factor limiting its delivery in the UK. The advent, in 2007 of a 
licensed product for grass pollen SLIT (Grazax, ALK-Abello) 
has transformed delivery of grass pollen desensitisation. In 
our service, we have treated well over 100 patients in that 
time with good clinical effect on their hay fever symptoms 
and very few side effects. It is anticipated that OIT and 
SLIT will continue to be developed for a wider range of 
allergens. Recent trials from UK and North America provide 
encouragement that this may be an effective strategy for the 
management of nut allergy in the future28,29.
Autoimmunity
Autoimmune reactions and diseases indicate that in certain 
circumstances, the normal immunological control mechanisms 
which are outlined above become defective. A number of 
mechanisms are thought to be responsible for this abnormal 
reactivity to “self-antigens”.  These include cross reactivity, 
molecular mimicry, provision of T cell epitopes, release of 
sequestered or cryptic antigens, failure of T cell regulation 
and anti-idiotype responses. The classical association between 
group A streptococcal infection and rheumatic heart disease 
is an example of “cross reactivity” in which the streptococci 
express antigens that are structurally similar to self antigens 
on cardiac muscle. Antibody and T cells specifically generated 
against the streptococcal antigen therefore cause damage to 
the structurally similar self proteins.
At a molecular level, the concept of “molecular mimicry” is 
also postulated. It is known that short molecular sequences 
(e.g. 5-amino-acid sequences) are commonly shared between 
microorganisms and self proteins. It is thought that both 
these mechanism may contribute to the development of 
autoreactivity. The potential linkage of foreign proteins 
(e.g. drugs or chemicals) to self proteins provides another 
mechanism for bypass of normal immunological control. B 
cells binding to the self-non-self complex have the potential 
to process and present the non-self component to T cells 
reactive to the foreign proteins. Thus it is possible for T cells 
to deliver inappropriate helper signals to B cells binding the 
self component, stimulating an autoimmune reaction. This 
is known as “provision of T cell epitopes”. Furthermore, 
some self antigens are not normally exposed to cells of 
the immune system and are said to be “sequestered”, e.g. 
lens proteins from the eye. Tissue damage can release such 
antigens and allow an immune response to occur e.g. after 
traumatic damage to one eye, the release of proteins can cause 
autoimmune damage to the other – sympathetic ophthalmia.
Cryptic antigens are those that are only released during the 
normal turnover of body proteins by antigen presenting 
cells. Because they are not normally expressed, tolerance 
does not develop and their release can allow the generation 
of autoimmune responses. It is likely that cryptic epitopes 
are normally only released in low concentrations; however 
coincidental factors such as infection or inflammation may 
be necessary to initiate the autoimmune response. T cell 
regulation has already been mentioned and a failure of T 
cell regulation (or suppression) has long been postulated as 
a mechanism for the generation of autoreactive responses. 
The balance of cytokines secreted in the microenvironment is 
important in influencing the nature of an immune response to 
a microorganism is therefore thought that the balance of T cell 
cytokine secretion in humans may be important in influencing 
autoimmune responses. Finally, the antigen binding sites of 
antibody molecules are known as idiotypes and it is possible 
that during a normal response to infection, a “second wave” 
of anti-idiotype antibodies is generated, directed not against 
the microorganism, but against these idiotypic sites, thereby 
generating auto antibodies
Two specific diseases highlight the importance of maintenance 
of central tolerance and effective regulatory T cell 
mechanisms30,31. In Autoimmune PolyEndocrinopathy-
Candidiasis-Ectodermal Dysplasia syndrome type 1 
(APECED Type 1) there are mutations in the autoimmune 
regulator gene (AIRE) on chromosome 21. These mutations 
lead to failure of apoptosis of autoreactive T cells and 
the consequent development of autoimmunity. Patients 
with  IPEX  (Immune dysfunction, Polyendocrinopathy, 
Enteropathy, X-linked) syndrome harbour mutations in the 
forkhead box P3 (FOXP3) gene in regulatory T cells, which 
leads to severe autoimmunity and immune deficiency.
In clinical terms, it is important to distinguish between those 
autoimmune reactions, (that  may occur as a consequence of 
infection, surgical procedures, drug treatment or increasing 
age and are characterised by the detection of autoantibodies 
in blood) and autoimmune disease.
Autoreactivity may only be temporary; indicating that the 
immune system can regain control of autoreactive lymphocyte © The Ulster Medical Society, 2011.
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clones after the “external insult” has been withdrawn.   
Autoimmune reactions are much more common than 
autoimmune disease. The detection of autoantibodies in blood, 
even in an unwell patient, does not therefore necessarily mean 
that the patient is suffering from an autoimmune disease, e.g 
10% of the population over 70 years of age have detectable 
antinuclear antibodies in serum. Autoimmune disease is said 
to be present only when tissue damage and symptoms occur 
and autoreactive antibodies or T cells are detected. 
Autoantibodies may be primary or secondary. Primary 
autoantibodies are rare in clinical practice and are defined 
as directly causing disease. Examples include the anti-TSH 
receptor antibody in Graves’ disease, the anti-acetylcholine 
receptor antibody in Myasthenia gravis or the anti-voltage 
gated calcium channel blocking antibodies in Lambert Eaton 
Myasthenic syndrome. Secondary autoantibodies occur as part 
of an autoimmune process, may be associated with specific 
disease (and be diagnostically helpful), but do not directly 
cause disease. Examples of secondary autoantibodies include 
antinuclear antibodies in systemic lupus erythematosus and 
antimitochondrial antibodies in primary biliary cirrhosis.
Auto inflammatory disease
A further group of clinical conditions, characterised by 
disordered immunological responses, is gaining increasing 
attention. These conditions are typically characterised by 
regular fevers, lymphadenopathy, rashes, joint pain, mouth 
ulcers etc. They are often referred to as Periodic Fevers, 
and our understanding of their pathogenesis and treatment 
has increased rapidly over recent years32. Several have very 
specific genetic causes and respond exquisitely to therapeutic 
immunological intervention. Familial Mediterranean Fever 
(FMF) is one of the best known of these conditions and is 
characterised by recurrent fever, serositis (abdominal, chest 
or joint pain), typically beginning before the age of 18 years. 
It is caused by a mutation in the MEFV gene which encodes 
the protein pyrin, which normally acts to indirectly inhibit 
production of the inflammatory cytokine IL-1.  Acute attacks 
are managed with analgesic and anti-inflammatory drugs 
and the long term administration of colchicines reduces the 
frequency and severity of attacks. TNF Receptor Associated 
Periodic Syndrome (TRAPS), previously known as Familial 
Hibernian Fever  (FHF) (as affected patients seemed to 
share Irish ancestory,) is associated with mutations in the 
TNF Receptor gene (TNFRSF1A). It has similar clinical 
features to FMF, but patients respond very well to treatment 
with the decoy TNF receptor, etanercept. A number of 
other periodic fever syndromes exist; including hyper IgD 
syndrome (HIDS) and Muckle Wells/Familial Cold Urticaria 
syndrome (associated with mutations of MVK and NLRP3 
genes respectively). In a number of these patients, specific 
immunological intervention with drugs such as the IL-1 
antagonist Anakinra is proving particularly effective33. 
CoNCLuSIoN
This mini-review has outlined the basic components of the 
immune system and how they work together to generate 
normal effective immune responses. I have also highlighted 
how the response may be defective through deficiency, 
over-reactivity (allergy) and dysregulation (autoimmune/
autoinflammatory diseases). Constraints of space dictate that 
each area has been touched on only superficially and therefore 
further suggested reading sources are listed for those who 
wish to explore these issues further. 
The field of primary immune deficiency has been 
revolutionised by the identification of single gene disorders 
which have assisted in disease classification and led to specific 
success in gene therapy. Allergic disease is also increasingly 
well understood in terms of basic science and it seems likely 
that we are on the threshold of a series of new developments 
in the area or desensitisation which should bring enormous 
benefits to patients. The combination of increased 
understanding of basic immunological inflammatory 
mechanisms and the development of novel therapeutic 
agents continues to deliver new effective treatments for 
immunologically mediated conditions that were once thought 
to be untreatable.  
For the clinician interested in the application of basic science 
to the investigation and treatment of a wide range of different 
diseases, affecting both paediatric and adult populations, it is 
difficult to think of a more exciting area of medicine.
The author has no conflict of interest.
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